<code id='32E390CECE'></code><style id='32E390CECE'></style>
    • <acronym id='32E390CECE'></acronym>
      <center id='32E390CECE'><center id='32E390CECE'><tfoot id='32E390CECE'></tfoot></center><abbr id='32E390CECE'><dir id='32E390CECE'><tfoot id='32E390CECE'></tfoot><noframes id='32E390CECE'>

    • <optgroup id='32E390CECE'><strike id='32E390CECE'><sup id='32E390CECE'></sup></strike><code id='32E390CECE'></code></optgroup>
        1. <b id='32E390CECE'><label id='32E390CECE'><select id='32E390CECE'><dt id='32E390CECE'><span id='32E390CECE'></span></dt></select></label></b><u id='32E390CECE'></u>
          <i id='32E390CECE'><strike id='32E390CECE'><tt id='32E390CECE'><pre id='32E390CECE'></pre></tt></strike></i>

          knowledge

          knowledge

          author:leisure time    Page View:982
          People taking notes while sitting around a meeting table
          Adobe

          It makes sense in theory for hospitals and startups to strike deals. Not only would doctors get first dibs on new health care technologies, their organizations would see windfalls if those startups hit it big.

          In practice, it often doesn’t work out that way. Doctors and other clinicians have their own way of doing things, and they typically don’t take kindly to an administrator telling them to learn a new product, especially if the goal is financial gain.

          advertisement

          Several health system-venture capital arrangements have fallen victim to this dynamic — but VC firm General Catalyst said this week it will buy nonprofit Summa Health, anyway.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          First Opinion Podcast: How to protect health care in times of war
          First Opinion Podcast: How to protect health care in times of war

          Injusttwoweeks,thebrutalityoftheIsrael-Hamasconflicthasshockedtheworld.Butoneofitsmostheartbreakinga

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

          DarronCummings/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne